Stay updated on SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial
Sign up to get notified when there's something new on the SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial page.

Latest updates to the SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial page
- Check3 days agoChange DetectedLocations section now lists participating states (Connecticut, Florida, Iowa, Massachusetts, Michigan, New York, North Carolina, Ohio, Oregon, Pennsylvania, Tennessee, Texas). The HHS Vulnerability Disclosure link was removed.SummaryDifference1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedAdded a PubMed auto-fill note stating that publications may not be about the study and included a page revision tag (v3.3.2). Removed the prior PubMed-source note and the older revision tag (v3.2.0).SummaryDifference0.1%

- Check40 days agoChange DetectedThe funding lapse notice was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check54 days agoChange DetectedMinor formatting/layout adjustments observed; no changes to core study data (title, conditions, interventions, eligibility criteria, or primary outcomes). To avoid being alert by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check83 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference2%

- Check90 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes provided.SummaryDifference0.0%

Stay in the know with updates to SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial page.